Related Experiment Videos
Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies
Abstract:
Nineteen patients with refractory solid malignancies received individualized combinations of mitomycin C conjugated murine monoclonal antibodies selected by immunohistochemical and flow cytometric screening of tumor specimens. There were no responses in this Phase I study. Thrombocytopenia precluded escalation above a mitomycin C dose of 60 mg per treatment cycle. Preclinical, clinical, and toxicity experiences with this investigational approach to the treatment of cancer are discussed.
Insights
This Phase I study found no patient responses using individualized mitomycin C conjugated monoclonal antibodies for solid tumors. Thrombocytopenia limited the mitomycin C dose, preventing further treatment escalation in refractory cancer patients.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Refractory solid malignancies present significant treatment challenges.
- Targeted therapies, including antibody-drug conjugates, are under investigation.
- Individualized treatment selection aims to improve efficacy.
Purpose of the Study:
- To evaluate the safety and preliminary efficacy of individualized mitomycin C conjugated murine monoclonal antibodies in patients with refractory solid malignancies.
- To determine the maximum tolerated dose (MTD) of mitomycin C in this combination therapy.
Main Methods:
- A Phase I clinical trial was conducted involving 19 patients.
- Tumor specimens underwent immunohistochemical and flow cytometric screening for individualized antibody selection.
- Patients received escalating doses of mitomycin C conjugated to selected murine monoclonal antibodies.
Main Results:
- No objective responses were observed in any of the 19 patients.
- Dose-limiting toxicity, specifically thrombocytopenia, occurred at a mitomycin C dose of 60 mg per treatment cycle.
- The maximum tolerated dose (MTD) was not reached due to toxicity.
Conclusions:
- Individualized combinations of mitomycin C conjugated murine monoclonal antibodies were not effective in this patient cohort.
- Thrombocytopenia is a significant toxicity that limits the dose of mitomycin C in this therapeutic approach.
- Further investigation into this investigational approach requires modification to mitigate toxicity or improve efficacy.